Castle Biosciences (CSTL)
NASDAQ:CSTL
Want to see CSTL full AI Analyst Report?
CSTL Stock Chart & Stats
$25.05
-$0.86(-2.67%)
At close: 4:00 PM EST
$25.05
-$0.86(-2.67%)
Day’s Range― - ―
52-Week Range$14.59 - $44.28
Previous CloseN/A
Volume108.23K
Average Volume (3M)278.06K
Market Cap
$730.79M
Enterprise Value$624.52M
Total Cash (Recent Filing)$299.50M
Total Debt (Recent Filing)$36.91M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
May 06, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding29,731,197
10 Day Avg. Volume267,219
30 Day Avg. Volume278,065
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)2.39
Price to Sales (P/S)3.28
P/FCF Ratio39.81
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue1.81
Enterprise Value/Gross Profit2.64
Enterprise Value/Ebitda47.55
Forecast
1Y Price Target
$46.60Price Target Upside86.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.17
Revenue Forecast (FY)$345.63M
Bulls Say, Bears Say
Bulls Say
DecisionDx‑Melanoma Clinical SupportPhysician feedback after an industry guideline update indicates DecisionDx‑Melanoma is likely to retain or expand its ordering base, supporting its competitive position.
Revenue GuidanceInitiated revenue guidance above analyst consensus signals management confidence in sustained sales momentum and potential upside to current expectations.
TissueCypher AdoptionStrong adoption of TissueCypher drove a substantial increase in ordering clinicians, highlighting a large addressable market and positioning the test as a core revenue driver.
Bears Say
AdvanceAD‑Tx CommercializationAdjustment of the commercialization approach for AdvanceAD‑Tx reflects limited adoption and casts doubt on the product's contribution to revenue growth.
DecisionDx‑SCC Volume And Reimbursement RiskWeaker DecisionDx‑SCC test volumes are creating pressure on that franchise and increase uncertainty until reimbursement reconsideration is resolved.
Castle Biosciences News
CSTL FAQ
What was Castle Biosciences’s price range in the past 12 months?
Castle Biosciences lowest stock price was $14.59 and its highest was $44.28 in the past 12 months.
What is Castle Biosciences’s market cap?
Castle Biosciences’s market cap is $730.79M.
When is Castle Biosciences’s upcoming earnings report date?
Castle Biosciences’s upcoming earnings report date is May 06, 2026 which is in 12 days.
How were Castle Biosciences’s earnings last quarter?
Castle Biosciences released its earnings results on Feb 26, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.259 by $0.179.
Is Castle Biosciences overvalued?
According to Wall Street analysts Castle Biosciences’s price is currently Undervalued.
Does Castle Biosciences pay dividends?
Castle Biosciences does not currently pay dividends.
What is Castle Biosciences’s EPS estimate?
Castle Biosciences’s EPS estimate is -0.49.
How many shares outstanding does Castle Biosciences have?
Castle Biosciences has 29,731,197 shares outstanding.
What happened to Castle Biosciences’s price movement after its last earnings report?
Castle Biosciences reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.259. Following the earnings report the stock price went down -7.246%.
Which hedge fund is a major shareholder of Castle Biosciences?
Currently, no hedge funds are holding shares in CSTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Castle Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$46.60 (86.03% Upside)
$46.60 (86.03% Upside)
Blogger Sentiment
Bullish
CSTL Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 10.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $210.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.1%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.45%
12-Months-Change
Fundamentals
Return on Equity
-5.27%
Trailing 12-Months
Asset Growth
9.98%
Trailing 12-Months
Company Description
Castle Biosciences
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
CSTL Company Deck
CSTL Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted strong commercial momentum across core franchises with notable volume growth (105K total test reports, +37%; TissueCypher +86%) and promising early uptake of new products (AdvanceAD-Tx ~500 orders in initial period). The company has a healthy cash balance (~$299.5M) and generated positive free cash flow in 2025. However, profitability and margin metrics deteriorated materially year-over-year (full year net loss $24.2M, adjusted EBITDA down to $44M from $75M, gross margin compressed to 69.2%), driven by lost DecisionDx-SCC revenue, a one-time amortization charge and higher operating expenses. Additional near-term risks include guideline and reimbursement uncertainties and timing for FDA clearance and reimbursement for new tests. Overall the operational growth story and cash strength balance against weakened profitability and reimbursement/timing risks.View all CSTL earnings summariesCSTL Stock 12 Month Forecast
Average Price Target
$46.60
▲(86.03% Upside)
Technical Analysis
Ownership Overview
2.34% Insiders
9.97% Mutual Funds
0.12% Other Institutional Investors
73.11% Public Companies and
Individual Investors